From the present study we conclude that the low FR-β expression in tumor tissue implies limited practical use of this receptor in diagnostic imaging and therapeutic purposes in ovarian, breast cancer and colorectal cancer. The gene discussed is FOLR2; the disease is breast carcinoma.